Compare NSSC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | DBVT |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | NSSC | DBVT |
|---|---|---|
| Price | $42.63 | $23.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $48.17 | $31.75 |
| AVG Volume (30 Days) | 478.9K | ★ 499.7K |
| Earning Date | 02-02-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ 0.75 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $192,025,000.00 | $5,502,000.00 |
| Revenue This Year | $13.32 | $1,768.71 |
| Revenue Next Year | $9.84 | $1,028.88 |
| P/E Ratio | $32.59 | ★ N/A |
| Revenue Growth | ★ 2.94 | N/A |
| 52 Week Low | $19.00 | $3.82 |
| 52 Week High | $48.12 | $26.19 |
| Indicator | NSSC | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 59.80 |
| Support Level | $41.71 | $20.25 |
| Resistance Level | $44.27 | $24.96 |
| Average True Range (ATR) | 1.68 | 1.57 |
| MACD | 0.54 | -0.12 |
| Stochastic Oscillator | 73.59 | 67.47 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.